cenicriviroc + pioglitazone

Cenicriviroc + pioglitazone is a combination of two oral small molecule drugs, both investigated separately and in combination for the treatment of nonalcoholic steatohepatitis (NASH) and related liver diseases. **Cenicriviroc** is a dual antagonist of the C-C chemokine receptor types 2 and 5 (CCR2 and CCR5), which inhibits the recruitment and activation of inflammatory cells, thereby reducing hepatic inflammation and fibrosis[1][5][7]. **Pioglitazone** is a thiazolidinedione that primarily acts as an agonist of peroxisome proliferator-activated receptor gamma (PPAR-γ), and to a lesser extent PPAR-α, thereby improving insulin sensitivity, modulating glucose and lipid metabolism, reducing gluconeogenesis, and lowering insulin resistance[2][4][6][8]. The combination is under investigation in clinical studies evaluating pharmacokinetics and safety in NASH, reflecting the multifactorial pathophysiology of the disease and the hypothesis that targeting both chemokine receptor-mediated inflammation/fibrosis and metabolic dysregulation may provide additive or synergistic benefits[3][7].